By inducing T cell expression of CD25, IL-2 enhances T cell signaling, thereby increasing the anti-tumor efficacy of cytotoxic T-lymphocytes (CTL) and chimeric antigen receptor T cells (CAR-T) used in immunotherapy (74). The gene discussed is IL2RA; the disease is neoplasm.